FDA Approves GlaxoSmithKline's Commit Lozenges

Helping you to quit smoking. Commit Lozenges are a smoking deterrent. It works by providing low levels of nicotine, which may help you to quit smoking by lessening physical symptoms of withdrawal.

Commit® Lozenge delivers strong, lasting medicine, providing controlled amounts of nicotine at a slower, less intense pace than cigarettes to help stop cravings before they start. It increases your chances of success by allowing you to focus your willpower on changing your behavior. Commit is also the first stop-smoking aid that offers you different strengths based on how soon you smoke your first cigarette in the morning–a method leading experts believe is a better indicator of nicotine dependence.

Throughout the 12-week period, Commit Lozenges slowly wean you from cigarettes until you no longer have the urge to smoke. It's a simple program that walks you step-by-step through the quitting process.

Commit Lozenge is a Nicotine Replacement Therapy produced by COPD International and manufactured by GlaxoSmithKline. Like its sibling products, Nicorette and the Nicoderm patch, the active ingredient is nicotine polacrilex. The Commit Lozenge comes in two strengths: 2mg and 4mg.